Article
Import of global high-risk clones is the primary driver of carbapenemase-producing Pseudomonas aeruginosa in Norway.
Journal of medical microbiology - 1 Jan 2025
Haldorsen Bjørg Christina, Samuelsen Rjan, Janice Jessin, Sare Miriam, Molvik Mari, Sundsfjord Arnfinn, The Norwegian Study Group On Cp-Pa, Pedersen Torunn
Abstract excerpt
Introduction. Infections by carbapenemase-producing Pseudomonas aeruginosa (CP-Pa) are concerning due to limited treatment options. The emergence of multidrug-resistant (MDR) high-risk clones is an essential driver in the global rise of CP-Pa.Hypothesis/Gap Statement. Insights into the molecular epidemiology of CP-Pa are crucial to understanding its clinical and public health impact. Despite the low incidence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.